Richard Alan Bender MD FACP

Cancer Genetics/Cancer Risk Assessment, Hematologic Oncology

Senior Consultant for Medical Affairs, Quest Diagnostics San Juan Capistrano, CA

26732 Crown Valley Pkwy Ste 271Mission Viejo, CA 92691
Phone+1 949-427-7933
Fax+1 949-715-1273

Dr. Bender is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bender's full profile Already have an account?

Education & Training

Los Angeles County-Harbor-UCLA Medical CenterResidency, Internal Medicine, 1970 - 1972
David Geffen School of Medicine at UCLAClass of 1970
University of California, Santa BarbaraB.A., Biology, With High Honors, 1966
University of California, Santa BarbaraBA, Biology, with High Honors, 1966

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 1971 - 2028
AZ State Medical License 2005 - 2022
NE State Medical License 2005 - 2021
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Medical Intern of the Year 1971
Regents Scholar State of California, 1966
Alpha Omega Alpha Medical Honor Society

Publications & Presentations

PubMed

40 citations
A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer
Yonghong Li, Andre R. Arellano, Lance A. Bare, Richard A. Bender, Charles M. Strom
Value in Health. 2017-04-01
43 citations
Molecular Classification of Unknown Primary Cancer
Richard A. Bender, Mark G. Erlander
Seminars in Oncology. 2009-02-01
50 citations
Distribution of the UGT1A1*28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals.
J. Liu, Kevin Qu, Anthony Sferruzza, Richard A. Bender
Anti-Cancer Drugs. 2007-07-01

Journal Articles

"Molecular Identification of Carcinoma of Unknown Primary (CUP) with Gene Expression Profiling"
Richard A. Bender, MD, Proceedings of the American Society of Clinical Oncology, 6/1/2007
"Preliminary Study of Three Tumor Markers for Hepatocellular Carcinoma: AFP, AFP-L3 and Glypican-3"
Richard A. Bender, MD, Proceedings of the American Society of Clinical Oncology, 6/1/2007
"A Multiplex Assay for Detection of Common Pediatric Sarcoma Tumor Markers"
Richard A. Bender, MD, Proceedings of the American Society of Clinical Oncology, 6/1/2007

Abstracts/Posters

Personalized Treatment of Advanced Metastatic Breast Cancer (MBC) Utilizing Target Now in a Community- Based Oncology Practice
Loesch D, Waisman J, Link J, Alarcon A, Boehm K, Ghazadpour A and Bender R,, San Antonio Breast Cancer Symposium, 12/7/2011
Differences in gene expression between primary chemotherapy-naïve prostate carcinomas and hormone-refractory prostate carcinomas
Basu G, McGinniss M, Alarcon A, Kemkes A and Bender R, ASCO-EORTC conference, San Francisco, 11/16/2011
Differences in gene expression between primary chemotherapy-naive prostate carcinomas and hormone-refractory prostate carcinomas
Basu G, McGinniss M, Alarcon A, Kemkes A and Bender R, ASCO-EORTC conference on “Molecular Targets and Cancer Therapeutics", 11/12/2011

Press Mentions

The Growing Disconnect Between Innovation and Execution in Molecular DiagnosticsOctober 18th, 2026
Telo Genomics Forms World-Class Multiple Myeloma Advisory Board in Preparation for the American Society of Hematology Annual MeetingDecember 8th, 2022
Telo Genomics Engages Key Opinion Leader to Form and Chair Myeloma Advisory BoardOctober 18th, 2022